Author details

Full Name

Torsten Pietsch

Affiliation

ORCID

Career Start Year

1988

Papers

523

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37875569	Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.	Nat Med	2024
36916248	Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.	Neuro Oncol	2023
36239995	A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.	Clin Cancer Res	2023
37947008	p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.		2023
36520193	Methylation class oligosarcoma may encompass IDH-wildtype gliomas.		2023
37287693	A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial <i>ZFTA-</i>fused ependymoma.	Neurooncol Adv	2023
36905695	Gliosarcoma with extensive extracranial metastatic spread and familial coincidence: A case report.		2023
36715306	Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups.	Neuro Oncol	2023
36895035	Supratentorial CNS-PNETs in children; a Swedish population-based study with molecular re-evaluation and long-term follow-up.	Clin Epigenetics	2023
37014508	Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.	Acta Neuropathol	2023
37260252	Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies.	Int J Cancer	2023
37379234	Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.	Neuro Oncol	2023
36928815	Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.	Nat Med	2023
36459208	Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.	Acta Neuropathol	2023
34933039	Pseudoprogression Is Frequent After Front-Line Radiation Therapy in Pediatric Low-Grade Glioma: Results From the German Low-Grade Glioma Cohort.	International Journal of Radiation Oncology Biology Physics	2022
36181537	Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.	Acta Neuropathol	2022
35901673	Long-term follow-up of surgical intervention pattern in pediatric low-grade gliomas: report from the German SIOP-LGG 2004 cohort.	J Neurosurg Pediatr	2022
35704157	Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.	J Neurooncol	2022
35892159	DNA methylation profiling improves routine diagnosis of paediatric central nervous system tumours: A prospective population-based study.	Neuropathol Appl Neurobiol	2022
36090026	Using CRISPR/Cas9 genome editing in human iPSCs for deciphering the pathogenicity of a novel transcription start site deletion.	Frontiers in Molecular Biosciences	2022
35570402	Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017.	Pediatric Blood and Cancer	2022
35501487	ATRT-SHH comprises three molecular subgroups with characteristic clinical and histopathological features and prognostic significance.	Acta Neuropathol	2022
35733513	Pediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates.	Neurooncol Adv	2022
36377725	The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro.	Journal of Cellular and Molecular Medicine	2022
37284158	Medulloblastoma and Cowden syndrome: Further evidence of an association.	Free Neuropathol	2022
33908610	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial.	Neuro Oncol	2022
34866327	Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma.	Pediatr Blood Cancer	2022
34919158	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3Â K27M Mutant Diffuse Midline Glioma.	Clinical Neuroradiology	2022
35190934	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.	J Neurooncol	2022
34964901	Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.	Neuro Oncol	2022
35158738	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study.	Cancers (Basel)	2022
34417833	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum.	Acta Neuropathol	2021
33971845	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany.	BMC Cancer	2021
33971689	Doubling Recruitment of Pediatric Low-grade Glioma within Two Decades does not change Outcome - Report from the German LGG Studies.	Klin Padiatr	2021
34077956	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.	Neuro Oncol	2021
33634344	Proportion of children with cancer that have an indication for genetic counseling and testing based on the cancer type irrespective of other features.	Familial Cancer	2021
33481105	Supratentorial ependymoma in childhood: more than just RELA or YAP.	Acta Neuropathol	2021
33631540	Telomerase reverse transcriptase promoter mutation- and O<sup>6</sup>-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?	Eur J Cancer	2021
34008056	Pediatric ependymoma: an overview of a complex disease.	Child's Nervous System	2021
34277025	Chemotherapy for adult patients with spinal cord gliomas.	Neurooncol Pract	2021
33673490	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status.	Pharmaceuticals (Basel)	2021
33870422	Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.	Journal of Neuropathology and Experimental Neurology	2021
33864086	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.	Neuro Oncol	2021
33196890	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).	Cancer Immunology, Immunotherapy	2021
33346834	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group.	Neuro-Oncology	2021
33128602	Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.	Childs Nerv Syst	2021
32619305	Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?	Brain Pathol	2021
33331885	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.	Neuro Oncol	2021
33113214	MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.	Int J Cancer	2021
34495383	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas.	Acta Neuropathol	2021